

Appendix Table F41. Adverse effects after duloxetine treatments compared to placebo (pooled results from RCTs)

Outcome	Studies	Patients	Rate active/control	Relative risk (95% CI)	Absolute risk difference (95% CI)	Number needed to treat (95% CI)	Attributable events (95% CI)	Bayesian odds ratio median (2.5; 97.5%)	Evidence
Total bilirubin above ULN	2 ^{312,350}	2,371	0.4/1.4	0.30 (0.08; 1.20)	-0.02 (-0.05; 0.00)			0.26 (0.06; 0.90)	Low
ALT above ULN/ Abnormal elevation in alanine aminotransferase	2 ^{312,350}	2,371	7.4/5.4	1.37 (1.00; 1.87)	0.015 (-0.001; 0.000)			1.38 (0.55; 3.34)	Low
AST above ULN/ Abnormal elevation in aspartate aminotransferase	2 ^{312,350}	2,371	5.3/4.0	1.06 (0.43; 2.64)	0.00 (-0.03; 0.00)			1.06 (0.28; 2.76)	Low
Anorexia	3 ^{312,350,378}	2,636	4.3/0.2	18.10 (5.66; 57.85)	0.04 (0.02; 24.39)	24 (17; 42)	41 (24; 58)	36.13 (9.10; 233.30)	Moderate
Anorgasmia	2 ^{312,381}	2,219	1.6/0.0	17.38 (2.31; 130.72)	0.02 (0.00; 58.82)	59 (31; 333)	17 (3; 32)		Low
Anxiety	3 ^{312,331,381}	2,670	2.4/0.7	3.21 (1.55; 6.66)	0.02 (0.01; 52.63)	53 (29; 200)	19 (5; 34)	4.11 (1.65; 11.50)	High
Appetite decreased	5 ^{234,312,331,339,381}	3,379	2.8/0.3	7.54 (3.21; 17.68)	0.02 (0.02; 43.48)	43 (32; 67)	23 (15; 31)	11.44 (4.43; 35.72)	High
Asthenia	4 ^{249,293,312,339}	4,993	1.7/0.3	5.03 (2.35; 10.75)	0.01 (0.00; 76.92)	77 (42; 333)	13 (3; 24)	7.47 (2.90; 23.90)	Moderate
Constipation	13 ^{234,249,254,279,293,312,331,339,350,355,378,381,393}	8,772	10.3/2.4	4.01 (3.26; 4.93)	0.08 (0.06; 12.82)	13 (11; 16)	78 (64; 91)	4.67 (3.55; 6.17)	High
Diarrhea	6 ^{254,279,312,331,355,381}	3,887	5.3/2.9	1.91 (1.38; 2.65)	0.02 (0.00; 52.63)			1.80 (1.01; 2.95)	Moderate
Dizziness	13 ^{234,249,251,254,279,293,312,331,339,350,355,378,393}	8,575	8.6/2.5	3.33 (2.69; 4.11)	0.07 (0.05; 14.93)	15 (12; 20)	67 (49; 84)	3.80 (2.89; 5.06)	High
Dry mouth	14 ^{234,249,251,254,279,293,312,331,339,350,355,378,381,393}	8,881	12.2/2.3	6.26 (4.22; 9.28)	0.12 (0.09; 8.70)	9 (7; 11)	115 (89; 141)	6.94 (5.07; 9.76)	High

Appendix Table F41. Adverse effects after duloxetine treatments compared to placebo (pooled results from RCTs) (continued)

Outcome	Studies	Patients	Rate active/control	Relative risk (95% CI)	Absolute risk difference (95% CI)	Number needed to treat (95% CI)	Attributable events (95% CI)	Bayesian odds ratio median (2.5; 97.5%)	Evidence
Fatigue	12 ^{234,249,251,279,312,331,339,350,355,378,381,393}	8,424	10.0/3.0	3.22 (2.66; 3.90)	0.08 (0.05; 12.99)	13 (10; 19)	77 (53; 100)	3.60 (2.75; 4.73)	High
Headache	10 ^{249,251,254,279,312,331,350,355,381,393}	7,706	9.3/5.9	1.58 (1.35; 1.86)	0.03 (0.02; 30.30)	30 (22; 50)	33 (20; 46)	1.67 (1.28; 2.21)	High
Hyperhidrosis	7 ^{239,249,312,331,339,350,378}	23,788	2.4/0.6	4.34 (3.29; 5.73)	0.04 (0.02; 28.57)	29 (20; 48)	35 (21; 49)	6.02 (3.85; 10.53)	High
Insomnia	12 ^{234,249,251,254,279,293,312,331,350,355,381,393}	8,495	9.3/2.3	3.76 (2.59; 5.47)	0.08 (0.05; 13.16)	13 (10; 21)	76 (47; 105)	4.35 (3.01; 6.26)	High
Nausea	14 ^{234,249,251,254,279,293,312,331,339,350,355,378,381,393}	8,881	22.7/5.4	5.02 (3.70; 6.82)	0.19 (0.15; 5.35)	5 (4; 7)	187 (149; 224)	6.25 (4.66; 8.50)	High
Somnolence	13 ^{234,249,251,254,279,293,312,331,339,350,378,381,393}	8,603	5.4/0.6	8.61 (4.58; 16.20)	0.06 (0.04; 16.95)	17 (13; 26)	59 (39; 80)	11.84 (6.99; 21.58)	High
Treatment associated adverse effects	9 ^{249,251,279,331,339,350,378,381,393}	5,646	62.7/45.4	1.36 (1.28; 1.44)	0.19 (0.15; 5.35)	5 (4; 7)	187 (150; 224)	2.53 (1.95; 3.44)	High
Vomiting	7 ^{249,251,312,331,350,381,393}	6,489	5.0/1.7	2.90 (2.14; 3.93)	0.03 (0.02; 32.26)	32 (26; 45)	31 (22; 39)	3.21 (2.16; 4.95)	High
Adverse effects	2 ^{234,381}	894	2.4/1.4	1.95 (0.34; 11.22)	0.01 (-0.02; 0.00)			1.94 (0.54; 8.21)	Low